FDA
-
-
-
-
-
-
-
NeuroPace Inc (NPCE) PT Raised to $20 at Leerink Partners
-
-
-
-
-
-
-
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
-
-
-
-
-
-
-
NeuroPace Inc (NPCE) PT Lowered to $15 at Wells Fargo
-
-
-
-
-
-
-
NeuroPace (NPCE) Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting
-
-
-
-
-
-
-
NeuroPace Strengthens Management Team with Two Key Appointments
-
-
-
-
-
-
-
NeuroPace Announces RNS System Enhancements Designed to Streamline Care
-
-
-
-
-
-
-
NeuroPace Announces First Patient Treated in Pivotal Study Evaluating the RNS System in Adolescents
-
323,580 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

